Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289303 | 0.76 | HIF1A (0.40) | CYP2C19CYP2D6TSHRHIF1AALDH1A1 | |
| SCHEMBL13685884 | 0.75 | ALDH1A1 (0.50) | CYP2C19CYP2D6TSHRHIF1AALDH1A1 | |
| SCHEMBL9179079 | 0.73 | TSHR (0.50) | CYP2C19CYP2D6TSHRHIF1AALDH1A1 | |
| SCHEMBL28736874 | 0.73 | ALDH1A1 (0.39) | CYP2C19CYP2D6TSHRHIF1AALDH1A1 | |
| SCHEMBL23927709 | 0.73 | PPARA (0.44) | TSHRCYP2C9 | |
| SCHEMBL168492 | 0.72 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL13979186 | 0.72 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL2015797 | 0.72 | ALDH1A1 (0.37) | CYP2C19ALDH1A1MEN1CYP2C9ALOX15 | |
| SCHEMBL2013789 | 0.71 | ALDH1A1 (0.33) | CYP2C19ALDH1A1MEN1CYP2C9ALOX15 | |
| SCHEMBL168034 | 0.70 | ARG1 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012088597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR ENHANCEMENT OF PHYSICAL OR MUSCULAR PERFORMANCE AND THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-07-05 | — | — | WO | disclosed |